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Summary
 
In a screen designed to identify genes that regulate T cell receptor (TCR)/CD3-mediated apop-
tosis, we found that high level expression of CD43 protected T cell hybridomas from activation-
induced cell death. The protection appears to result from its capacity to block Fas-mediated
death signals rather than from inhibition of the upregulation of Fas and/or Fas ligand after T
cell stimulation. We found that peripheral CD4
 
1
 
 T cells can be divided into two subsets based
on the level of CD43 surface expression. The CD4
 
1
 
CD43
 
low
 
 subset exhibits a naive T cell
phenotype, being CD62L
 
high
 
CD45RB
 
high
 
CD44
 
low
 
, whereas CD4
 
1
 
CD43
 
high
 
 cells exhibit a mem-
ory phenotype, being CD62L
 
low
 
CD45RB
 
low
 
CD44
 
high
 
. Recent studies have demonstrated that
engagement of TCR and Fas induces naive CD4
 
1
 
 T cells to undergo apoptosis, and the same
treatment enhances the proliferation of memory CD4
 
1
 
 T cells. We confirm here that periph-
eral CD4
 
1
 
CD43
 
high
 
 T cells are resistant to TCR/CD3-mediated cell death. These results sug-
gest that the expression levels of CD43 on naive and memory CD4
 
1
 
 T cells determine their
susceptibility to Fas-dependent cell death and that high level expression of CD43 may be used
as a marker to define CD4
 
1
 
 memory T cells. Expression of CD43 provides a novel mechanism by
which tumor cells expressing abnormally high levels of CD43 may escape Fas-mediated killing.
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1
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A
 
fter generation of a successful T cell response, a majority
of the activated T cells die, and a minority survive to
become resting memory cells (1). Memory T cells differ from
naive T cells not only in the expression of surface markers
but also in their functionality. Compared with naive T cells,
memory T cells express lower levels of CD62L and CD45RB
and higher levels of CD44. Memory T cells also respond
faster, have a lower activation threshold, and secrete a wider
range of cytokines than naive T cells. In addition, recent
studies have demonstrated that, compared with naive CD4
 
1
 
T cells, memory CD4
 
1
 
 T cells are resistant to TCR-medi-
ated, Fas-dependent apoptosis (2–4). Engagement of TCR
or TCR plus Fas on naive CD4
 
1
 
 T cells induces these cells
to undergo apoptosis, whereas Fas engagement may en-
hance the proliferation of memory CD4
 
1
 
 T cells (2–4).
Studies on activation-induced cell death (AICD) of T cell
hybridomas have been fruitful for understanding the mo-
lecular mechanisms of T cell apoptosis. After TCR stimula-
tion, T cell hybridomas upregulate Fas and FasL (ligand).
Autocrine stimulation of Fas by FasL triggers the death
pathway via the recruitment of adaptors to the cytoplasmic
tail of Fas (5). CD43 (leukosialin, sialophorin) is a highly
glycosylated transmembrane protein expressed on the sur-
faces of all hematopoietic cells except mature B cells and
erythrocytes (6). Previous studies suggest that CD43 may
regulate multiple cellular functions, such as cell adhesion,
activation, and proliferation as well as cell survival and apop-
tosis. However, the precise function of CD43 remains un-
known due to conflicting results. Cross-linking of CD43
may enhance T cell proliferation (7), and it can act as a co-
stimulatory molecule independent of CD28 (8). However,
T cells from CD43-deficient mice are hyperresponsive after
both in vivo and in vitro activation, indicating a negative
regulatory role for CD43 in T cell activation (9). Although
an anti-CD43 mAb has been shown to inhibit T cell bind-
ing to lymph node and Peyer’s patch high endothelial
venule and homing from the blood into second lymphoid
tissues (10), T cells from CD43-deficient mice homed sig-
nificantly more frequently to secondary lymphoid organs
compared with wild-type T cells (11). Certain studies have
shown that engagement of CD43 induces apoptosis of T
cells and hematopoietic progenitor cells (12, 13); CD43
was also shown to promote B cell survival when ectopically
expressed (14).
In a search for genes that regulate TCR/CD3-mediated
AICD, we found that CD43 can protect T cells when ex-
pressed at high levels. This protection appears to be due to
a blockade of Fas function by CD43. Our findings shed
new light on the significance of CD43 expression in lym-
phoid and nonlymphoid tissues. 
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Materials and Methods
 
Cell Lines.
 
A subclone of DO11.10 T hybridoma cells with a
low survival rate in PMA plus ionomycin was used for expression
cloning. 
 
f
 
NX-Ampho is a retrovirus packaging cell line (15).
DO11.10 cell line expressing a tailless version of human CD2
(DO11.10hCD2) as control was described previously (16). DO11.10
cells expressing high levels of CD43 were generated by transduction
of mouse CD43 cDNA using the pMX retrovirus vector, followed
by FACS
 
®
 
 sorting for CD43 expression. Cells were cultured in
DMEM containing 10% FCS, 2 mM glutamine, 25 mM Hepes, 50
 
m
 
M 
 
b
 
-ME, 100 U/ml penicillin, and 100 
 
m
 
g/ml streptomycin.
 
mAbs and Reagents.
 
Anti–human CD2 mAb 35.1 (American
Type Culture Collection) was purified and labeled in our labora-
tory. The following mAbs were purchased from PharMingen:
purified or PE–anti-CD3 (145-2C11), FITC– or PE–anti-CD4
(GK1.5), FITC–, PE–, or biotin–anti-CD8
 
a
 
 (53-6.7), FITC– or
PE–anti-CD43 (S7), PE–anti-CD69 (H1.2F3), biotin–anti-FasL
(Kay-10), PE–anti-Fas (Jo2), biotin–anti-CD62L (MEL-14),
biotin–anti-CD45RB (16A), and biotin–anti-CD44. Ceramide
and staurosporine were purchased from Calbiochem Corp. Re-
combinant human IL-2 was purchased from Chiron Corp.
 
Expression Cloning.
 
Expression cloning was performed as de-
scribed (16). In brief, a thymocyte cDNA library in the retroviral
vector pMX (17) was transfected into the 
 
f
 
NX-Ampho packaging
cell line using CaPO
 
4
 
 precipitation, and retrovirus-containing su-
pernatant was harvested 2 d later. DO11.10 cells were infected
with the retrovirus supernatant. A total of 5 
 
3 
 
10
 
6
 
 DO11.10 cells
were infected, as assessed using control pMX-hCD2 retrovirus infec-
tion. 2 d after the infection, DO11.10 cells were placed into 96-well
plates (5 
 
3
 
 10
 
4
 
 cells/well) and selected for survival and growth in
the presence of PMA (10 ng/ml) plus ionomycin (0.2 
 
m
 
g/ml). Re-
sistant clones were identified after 2–4 wk in culture. cDNA inserts
were amplified by reverse transcriptase–PCR and sequenced.
 
Flow Cytometric Analyses.
 
Before staining, cells were incu-
bated with a mAb to FcR (2.4G2) and then sequentially stained
with an excess of biotinylated mAb, PE–streptavidin, or FITC–
and PE–conjugated mAbs on ice for 30 min and washed with
PBS containing 0.1% BSA. Data were collected on 1–5 
 
3
 
 10
 
4
 
cells on a FACScan™ flow cytometer (Becton Dickinson) using
CELLQuest™ software.
 
Apoptosis Assay.
 
24- or 96-well tissue culture plates were pre-
coated with rabbit anti–hamster antiserum (50 
 
m
 
g/ml) overnight at
37
 
8
 
C, washed with HBSS, and coated with anti-CD3 mAb (145-
2C11) at the amount indicated in figure legends. Hybridoma cells
were added to the plates for the indicated time (see figure legends),
harvested, and analyzed. Alternatively, PMA plus ionomycin was
added to the culture instead of anti-CD3 mAb. For the thymidine
incorporation assay, 2 
 
3
 
 10
 
4
 
 hybridoma cells per well were added
to 96-well plates, cultured for 20 h, and labeled with [
 
3
 
H]thymi-
dine (1 
 
m
 
Ci/well, 25 Ci/mmol; New England Nuclear) for a fur-
ther 4 h. For TCR-induced apoptosis of CD4
 
1
 
 cells, splenocytes
were activated with Con A (5 
 
m
 
g/ml) for 2 d, treated with methyl-
 
a
 
-
 
d
 
-mannopyranoside (10 mg/ml) at 37
 
8
 
C for 30 min, washed
twice with PBS, and then cultured in 100 U/ml human IL-2 for an
additional 2 d. The cells were then harvested and plated on an anti-
CD3–coated plate. 16–24 h later, cells were quantitated by trypan
blue exclusion and FACS
 
®
 
 analysis.
 
Results
 
Identification of CD43 as an Inhibitor of AICD.
 
We em-
ployed an expression cloning strategy to identify genes that
 
regulate AICD in a T cell hybridoma. We infected DO11.10
cells with a thymocyte cDNA library packaged in a retrovi-
rus and selected for cells that could grow in the presence of
PMA plus ionomycin. cDNA inserts from resistant clones
were sequenced, revealing that one of the inserts encoded a
full length CD43. To confirm the antiapoptotic effect of
CD43, we transduced DO11.10 cells with either the full
length CD43 or a tailless human CD2 as control. DO11.10
cell lines expressing high levels of CD43 were established
by fluorescence-activated cell sorting. As shown in Fig. 1 A,
DO11.10hCD2 control cells express a low level of en-
dogenous CD43 on their surfaces. After transduction with
pMXCD43, we isolated DO11.10 cell lines expressing
 
z
 
6–20-fold higher surface levels of CD43 compared with
control cells (Fig. 1 A). Interestingly, DO11.10CD43
 
high
 
cells expressed two- to threefold lower levels of CD3 on
their surfaces compared with DO11.10hCD2 control cells
(Fig. 1 A). The lower CD3 surface staining was not due to
nonspecific blockade of cell surface accessibility, as the ex-
pression levels of other surface molecules such as CD2 and
CD5 were not changed (data not shown).
To examine the effect of high level expression of CD43 on
activation-induced apoptosis, we measured [
 
3
 
H]thymidine
uptake of DO11.10hCD2 control and DO11.10CD43
 
high
 
cells in the absence or presence of anti-CD3 mAb or PMA
plus ionomycin. [
 
3
 
H]thymidine incorporation by these cells
closely correlated with their viability, measured by either
propidium iodide uptake or trypan blue exclusion (16). As
shown in Fig. 1 B, DO11.10 cells expressing high levels of
CD43 were protected from anti-CD3–induced death. In
contrast, control cells were readily induced to undergo ap-
optosis. We further determined whether the antiapoptotic
effect in DO11.10CD43
 
high
 
 cells could be due to a lowered
TCR/CD3 surface expression by using PMA plus iono-
mycin as a stimulus for AICD, which bypasses the TCR.
DO11.10CD43
 
high
 
 cells were also refractory to apoptosis
induced by PMA plus ionomycin (Fig. 1 B). The protec-
tion from AICD by CD43 correlated with its expression
level, and the dosage effect was more pronounced when
these cells were stimulated with anti-CD3, possibly due to
some steric hindrance of CD43 imposed on the interaction
of TCR/CD3 with the plate-bound anti-CD3 mAb. Next,
we tested the effect of high level expression of CD43 on
apoptosis induced by other stimuli. DO11.10 cells expressing
high levels of CD43 were protected from apoptosis only in
the presence of low amounts of staurosporine and were not
protected from ceramide-induced killing (Fig. 1 B).
 
High Level Expression of CD43 Does Not Inhibit T Hybrid-
oma Activation and Upregulation of Fas and FasL.
 
Previous
studies have demonstrated that CD43 acts as a negative reg-
ulator of T cell activation, presumably due to its highly
charged nature and its large size (9). To examine the effect
of high level expression of CD43 on T cell hybridoma
activation, we stimulated control DO11.10hCD2 and
DO11.10CD43
 
high
 
 cells with either plate-bound anti-CD3
mAb or PMA plus ionomycin for 6 h and monitored the
upregulation of Fas, FasL, and CD69 by FACS
 
®
 
 analy- 
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sis. Before TCR stimulation, the expression of Fas on
DO11.10CD43
 
high
 
 cells was lower compared with control
cells (Fig. 2). However, both Fas and FasL were upregu-
lated by anti-CD3 stimulation of DO11.10CD43
 
high
 
 cells
 
(Fig. 2), even though these cells express lower levels of CD3
(Fig. 1 A). The T cell activation marker CD69 was also up-
regulated to a similar level in both cell types (Fig. 2). Simi-
larly, PMA plus ionomycin upregulated expression of these
three markers in control and CD43
 
high
 
 cells (data not shown).
These data indicate that high levels of CD43 expression did
not obviously affect the activation of these T hybridoma
cells and the upregulation of Fas and FasL and suggest that
high level expression of CD43 may interfere with the death
signal initiated through the Fas molecule.
 
CD4
 
1
 
CD43
 
high
 
 Peripheral T Cells Exhibit a Memory Pheno-
type.
 
Previous studies have shown that TCR/CD3-medi-
ated apoptosis of CD4
 
1
 
 T cells in vitro is primarily induced
through Fas, whereas CD8
 
1
 
 T cell death is primarily in-
duced through TNFR (18). Given the antiapoptotic effect
exhibited by high level expression of CD43 on T hybri-
doma cells, we examined its expression on peripheral T
lymphocytes. As shown in Fig. 3 A, splenic CD4
 
1
 
 T cells
of unimmunized, young adult C57BL/6 mice can be divided
into two subsets based on CD43 expression. CD4
 
1
 
CD43
 
high
 
cells consist of 10–15% of the total CD4
 
1
 
 T cells, and the
surface expression of CD43 on these cells is six- to eight-
fold higher than that on CD4
 
1
 
CD43
 
low
 
 cells (Fig. 3 A). In-
terestingly, splenic CD8
 
1
 
 T cells exhibit uniformly high
levels of CD43 on their surfaces (Fig. 3 A). To further deter-
mine the phenotype of CD4
 
1
 
CD43
 
high
 
 and CD4
 
1
 
CD43
 
low
 
T cells, we analyzed these cells with three-color staining
using mAbs directed against CD62L, CD45RB, and CD44.
Surprisingly, the two CD4
 
1
 
 subsets expressing high or low
levels of CD43 exhibited a characteristic phenotype of mem-
ory or naive T cells, respectively (Fig. 3 B). CD4
 
1
 
CD43
 
high
 
T cells express high levels of CD44 and low levels of
Figure 1. High level expression of CD43 protects T hybridoma cells from AICD. (A) FACS® analysis of surface expression of CD43 and CD3 on
DO11.10hCD2 control and DO11.10CD43high cell lines. Shown are the histogram profiles of DO11.10hCD2 control and two individual
DO11.10CD43high cell lines. Histograms on the left represent isotype-matched antibody staining for background control. (B) DO11.10hCD2 control
cells (h) and two DO11.10CD43high (e, number 1; s, number 2) cell lines as shown in A were cultured in plates coated with 2C11, PMA (10 ng/ml)
plus various amounts of ionomycin, or different concentrations of staurosporine and ceramide and assayed for their [3H]thymidine incorporation. Incor-
poration of individual cell lines cultured in medium alone is calculated as 100%.
Figure 2. Effect of high level expression of CD43 on the upregulation
of Fas, FasL, and CD69. FACS® analysis of cell surface expression of Fas,
FasL, and CD69 in DO11.10hCD2 control or DO11.10CD43high cell
line after TCR-mediated activation. Cells were activated on 2C11-coated
plates for 5 h, and the cell surface phenotype was examined (filled curve,
before activation; unfilled curve, after activation). 
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CD62L and CD45RB, whereas CD4
 
1
 
CD43
 
low
 
 T cells ex-
press low levels of CD44 and high levels of CD62L and
CD45RB. Peripheral CD4
 
1
 
 and CD8
 
1
 
 T cells from lymph
nodes exhibited a similar phenotype to splenic T cells in
the above analysis (data not shown). These results suggest
that CD43 may be used as a marker to define memory
CD4
 
1
 
 T cells.
 
CD4
 
1
 
CD43 
 
high
 
 T Cells Are Resistant to TCR/CD3-medi-
ated Cell Death.
 
Recent studies have demonstrated that
naive CD4
 
1
 
 T cells are more susceptible to TCR-mediated,
Fas-dependent cell death compared with memory phenotype
CD4
 
1
 
 T cells (2–4). To test whether the CD4
 
1
 
CD43
 
high
 
 pri-
mary cells are resistant to TCR/CD3-mediated cell death,
we used an in vitro assay for AICD of CD4
 
1
 
 T cells. Sple-
nocytes from normal C57BL/6 mice were activated with
Con A for 2 d, followed by culture in a high concentration
of IL-2 for another 2 d. The activated cells were then re-
stimulated with plate-bound anti-CD3, and cells that sur-
vived the restimulation were analyzed by FACS
 
®
 
. After re-
stimulation with plate-bound anti-CD3, a majority of the
CD4
 
1
 
 T cells were readily induced to undergo apoptosis,
whereas CD8
 
1
 
 T cells did not suffer obvious cell loss in
16–24-h assay. When live cells from the restimulation plates
were stained with CD4 and CD43, it was observed that
only those CD4
 
1
 
 cells expressing high levels of CD43 sur-
vived anti-CD3 stimulation (Fig. 4). These results demon-
strate that CD4
 
1
 
CD43
 
high T cells are resistant to TCR/
CD3-mediated cell death and imply that CD43 may deter-
mine this property of memory CD41 T cells.
Discussion
Several recent studies have demonstrated that CD41 mem-
ory T cells are resistant to TCR-mediated, Fas-dependent cell
death, whereas CD41 naive T cells succumb (2–4). In this re-
port, we show that high level expression of CD43 protects T
cell hybridomas from AICD. Peripheral CD41CD43low T
cells exhibit a naive phenotype, whereas CD41CD43high
exhibit a memory phenotype, suggesting that the surface
expression levels of CD43 on CD41 naive and memory T
cells determine their susceptibility to TCR-mediated, Fas-
dependent cell death.
How is the inhibition of TCR/CD3-mediated cell death
by high level expression of CD43 achieved? CD43 has
been shown to have multiple, sometimes contradictory
functions. This may be due to its structural features and the
systems that have been used to study its function. CD43 is
arguably the most abundant protein on the T cell surface
(19). It extends 45 nm from the cell surface, at least six
times the height of the TCR. It is also highly O-glycosy-
lated and bears numerous sialic acid residues. The antiadhe-
sive and antiproliferative effects mediated by CD43 are
thought to result from a physical barrier formed by this
highly negatively charged and rigid rod–like structure.
However, this functional model of CD43 has been chal-
lenged by recent experiments showing that the cytoplasmic
domain of CD43 plays an important role in its function
(20, 21). Moreover, the extracellular portion of CD43 may
also be highly dynamic and actively interact with other sur-
face structures. In support of this notion, a recent study
showed that CD43 moves away from the contact sites of T
Figure 3. Phenotypic analysis of CD41 T cells in the spleens of
C57BL/6 mice. (A) Expression of CD43 on CD4 and CD8 T cells. Shown
are the dot plot profiles of splenocytes double stained with anti-CD43 plus
anti-CD4 or anti–CD8. Gated regions represent CD43low and CD43high
cells. (B) Expression of CD62L, CD45RB, CD44, and CD43 on CD41 T
cells. Shown are histogram profiles of CD62L, CD45RB, and CD44 stain-
ing on CD41CD43low and CD41CD43high cells as gated in A.
Figure 4. CD41CD43high T cells are resistant to TCR/CD3-mediated
cell death. Splenocytes were activated with Con A, cultured in IL-2, and
restimulated with plate-bound 2C11 for 18 h in the presence of IL-2.
Live cells were electronically gated and analyzed for their expression of
CD43 and CD4. Control cells were cultured in IL-2 alone.1907 He and Bevan Brief Definitive Report
cells and APCs, whereas CD45, similarly large in size and
strongly negatively charged, does not (22). In addition,
CD43 was reported to be physically associated with the
TCR/CD3 complex (23). Several mechanisms can be en-
visioned for the anti-apoptotic effect caused by high level
expression of CD43. First, highly expressed CD43 might
block Fas signaling by physically preventing the interaction
between FasL and Fas. Alternatively, it may prevent Fas
from forming trimers. The fact that high level expression of
CD43 on DO11.10 specifically decreases the expression of
TCR/CD3 and Fas indicates that they may physically in-
teract or form surface complexes with each other. Further-
more, high level expression of CD43 may interfere with
the recruiting of death signaling molecule by Fas or inhibit
the activation of caspases. Overexpression of Toso, a sur-
face protein that contains an Ig domain, was shown to in-
hibit Fas signaling by upregulating the caspase-8 inhibitor
cFLIP (cellular FLICE [FADD-like IL-1b–converting en-
zyme]-inhibitory protein; reference 15). We have not ob-
served differences in the expression of cFLIP in DO11.10
control cells and CD43high–expressing cells (our unpub-
lished observation). It is interesting to note that although
CD43highCD41 T cells from spleen and lymph nodes ex-
press six- to eightfold higher levels of CD43 on their sur-
faces than CD43lowCD41 cells, these cells are much easier
to activate by either anti-CD3 or Con A than CD43low
CD41 cells (our unpublished data), in agreement with pre-
vious studies showing that memory T cells have a lower
threshold for activation (1). These data further argue against
the model that CD43 negatively regulates T cell activation
by increasing the stimulation threshold or by physically
hindering the interaction between T cells and APCs. Our
attempt to investigate whether the cytoplasmic tail of CD43
is required for the inhibition of AICD was inconclusive. A
tailless CD43 retaining two amino acids of the cytoplasmic
tail can be expressed at only two- to threefold higher levels
than the endogenous CD43 on DO11.10 cells, and this
tailless version of CD43 had no obvious antiapoptotic ef-
fect (our unpublished data).
We propose that high level expression of CD43 be used
as a surface marker to define CD41 memory T cells in
C57BL/6 mice. Our results further suggest that CD43 may
protect activated cells from AICD. In addition, we note that,
correlating with their resistance to Fas-mediated killing,
CD81 T cells uniformly express high levels of CD43.
The protection against Fas-mediated killing by high level
expression of CD43 may provide a novel mechanism for its
role in tumorigenesis. CD43 has been shown to be overex-
pressed in Friend erythroleukemia cells (24) and abnor-
mally expressed in nonhematopoietic tumor lines such as
colon carcinoma and adenoma cells (25–27). Surface ex-
pression of CD43 diminishes susceptibility of target cells to
T cell–mediated cytolysis (28), and the obvious implication
is that CD43 expression on tumor cells protects them
against lymphoid effectors bearing FasL.
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